Enhanced Telomerase-Activating Compounds for Fertility and Related Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses improved telomerase-activating compounds and compositions for treating diseases, disorders, and conditions related to fertility and preserving same. The new claims provide enhanced formulations, dosing regimens, and combinations with fertility-promoting agents to optimize telomerase expression and activity, leading to better fertility outcomes.
Background and Problem Solved
The original patent disclosed telomerase-activating compounds for fertility and related applications, but had limitations in terms of optimizing telomerase expression, controlling dosing, and addressing individual variability. The new inventive concept addresses these limitations by introducing controlled-release formulations, personalized dosing regimens, and combinations with antioxidants and fertility-promoting agents.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for enhancing fertility in a subject, featuring a telomerase-activating compound and a fertility-promoting agent. The telomerase-activating compound is administered in a controlled-release formulation to optimize telomerase expression and activity. Additionally, a method for improving fertility outcomes in a subject involves administering a telomerase-activating compound in a personalized dosage regimen based on the subject's individual telomerase expression profile. Furthermore, a composition for promoting fertility in a subject includes a telomerase-activating compound and an antioxidant, which enhances the bioavailability and efficacy of the telomerase-activating compound.
Novelty and Inventive Step
The new claims introduce novel combinations of telomerase-activating compounds with fertility-promoting agents, controlled-release formulations, and personalized dosing regimens, which are not obvious from the original patent. These improvements provide a significant enhancement to the original inventive concept, making it more effective and efficient.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different formulations, such as oral, injectable, or topical, and various combinations of telomerase-activating compounds with other fertility-promoting agents. Additionally, the inventive concept could be adapted for use in other applications, such as cancer treatment or regenerative medicine.
Potential Commercial Applications and Market
The enhanced telomerase-activating compounds and compositions have significant commercial potential in the fertility and reproductive health markets, as well as in related industries such as cancer treatment and regenerative medicine. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers specializing in fertility and reproductive health.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/09 |
| A | A61 | A61K31/137 |
| A | A61 | A61K31/4025 |
| A | A61 | A61K31/4545 |
| A | A61 | A61K31/5377 |
| A | A61 | A61K31/66 |
| A | A61 | A61P15/08 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Reproductive medicine, pharmaceutical compositions, and telomerase activation, specifically focused on fertility enhancement and cellular therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology, pharmacology, or reproductive medicine, possessing expertise in drug formulation, cellular signaling, and fertility treatment strategies
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core telomerase activation methodology. The disclosed improvements in controlled-release formulations, personalized dosing, and combination therapies represent logical incremental advancements that would be apparent to a skilled researcher seeking to optimize fertility treatments. These variations demonstrate standard pharmaceutical engineering approaches to enhancing drug delivery and therapeutic efficacy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,516 |
|---|---|
| Title | Telomerase activating compounds for use in fertility and related applications |
| Assignee(s) | Neuromagen Pharma, Ltd. |